Genome BC, a non-profit research organization, leads genomics innovation on Canada’s West Coast and facilitates the integration of genomics into society. Their major investors are the Province of British Columbia and the Government of Canada through Genome Canada and Western Economic Diversification Canada. This funding is complemented by partnerships with many national and international public and private funding organizations to drive BC’s bioeconomy.

Genome British Columbia

The E-Fund (VANTEC Entrepreneurs Fund VCC Inc.) was established in 2011 to invest in promising new ventures in British Columbia in a wide range of industry sectors. They are focused on co-investing with other angel investors and early-stage venture capital firms in seed-stage companies with high growth opportunities.  The E-Fund  involves specific investors in the investment due diligence process depending on their industry experience and knowledge and their particular technical expertise.  It is their goal to become the ‘Go-to Braintrust’ for active and in-depth angel investing.

E-Fund

entrepreneurship@UBC propels UBC innovations out into the world through venture creation, providing UBC students, researchers, faculty members, alumni and staff with the resources, networks, and funding they need to succeed.  As one of the world’s top 40 research universities with 80,000 students, faculty and staff and over $650M annual research funding, UBC has long been a catalyst for innovation. Part of the Innovation UBC network, entrepreneurship@UBC supports UBC ventures and entrepreneurs to generate social and economic impacts in B.C. and around the world. To date, entrepreneurship@UBC ventures have raised more than $221 million in funding, generated more than $30 million in revenue and hired more than 600 employees, stimulating the economic and social landscape of B.C. while building anchor companies that have a global impact.

entrepreneurship@UBC

UBC Seed Fund is an investment firm that invests in seed-stage enterprises. These early equity investments are critical in assisting entrepreneurs in gaining traction in their enterprises and serving as a bridge to additional outside investment capital.

UBC Seed Fund

Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases. Its main offerings include pioneering scientific breakthroughs and expanding access to their medicines, with the ultimate goal of preventing and curing disease.

Novo Nordisk

Radical Ventures is an early-stage venture capital firm investing in entrepreneurs applying deep technology to transform massive industries. With a primary focus on artificial intelligence, Radical Ventures partners with entrepreneurs with global ambition to build enduring companies. The firm is based in Toronto, Canada, with offices in London (UK), and Palo Alto (US)

Radical Ventures

Pangaea Ventures invests in companies solving fundamental problems in the world such as climate change, food/water insecurity and poor health outcomes. It looks for companies with hard tech solutions. It is an impact investor and a hard tech investor.

Pangaea Ventures

Pallasite Ventures provides early-stage financing for high-growth companies across a variety of industries. It was founded by David Light and is based in Chicago, Illinois.

Pallasite Ventures

There is more to choosing an investor than selecting the term sheet with the highest valuation. Strategic capital, in its true form, extends the founding team’s capacity. That’s what we do at Rhino. We invest in companies where we can add tangible value.  We’ve been on the other side of the table and appreciate the importance of funder and founder alignment. From startup, growth to exit; it is entrepreneurial ambition that drives value, not venture capitalists. We invest in individuals; trust and values fit are a centerpiece in every investment.

Rhino Ventures

Aspect Biosystems

Aspect Biosystems is a biotechnology company developing bioprinted tissue therapeutics to transform how we treat disease. By combining its proprietary microfluidic 3D bioprinting technology, therapeutic cells, and materials science, Aspect is creating a pipeline of allogeneic cell-based tissue therapeutics to replace or repair damaged organ functions. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine.

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat currently incurable diseases. The company is creating next-generation cell therapies by applying its full-stack tissue therapeutic platform, which combines proprietary bioprinting technology, computational tissue design, therapeutic cells, and biomaterials. Aspect's bioprinted tissue therapeutics are designed to replace, repair, or supplement biological functions inside the body to treat serious metabolic and endocrine diseases such as type one diabetes, obesity, and liver disease.

based Aspect Biosystems to advance innovative health treatments for Canadians

Aspect Biosystems Announces $200 Million Partnership with the Governments of Canada and British Columbia to Advance Development of Bioprinted Tissue Therapeutics

Vancouver, B.C., tissue ‘bioprinting’ company inks $75M deal with Novo Nordisk for diabetes, obesity

Aspire to Tech - Aspect Biosystems

Aspect Biosystems launches new RX1 Bioprinter Grant Program

Aspect Biosystems 3D bioprinting selected for $2.2M cancer drug development project

Aspect Biosystems Receives Over $3.6 Million From the Government of Canada

3D Bioprinting Companies

Canadian Government Invests $75M More in Aspect Biosystems - 3DPrint.com

Aspect Biosystems 3D bioprinting kidney tissue with Maastricht University

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Bioprinting

Aspect Biosystems Secures $72.75 Million Government Investment to Advance Bioprinted Tissue Therapeutics

Johnson & Johnson

To use 3D printing to explore treatment of ‘one of the most common knee injuries’.

Developing software solutions and applications for designing and managing the bioprinting production process.

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat currently incurable diseases. The company is creating next-generation cell therapies by applying its full-stack tissue therapeutic platform, which combines proprietary bioprinting technology, computational tissue design, therapeutic cells, and biomaterials. Aspect's bioprinted tissue therapeutics are designed to replace, repair, or supplement biological functions inside the body to treat serious metabolic and endocrine diseases such as type one diabetes, obesity, and liver disease.
Aspect partnered with Novo Nordisk in a landmark USD 2.6 billion collaboration to develop bioprinted tissue therapeutics for diabetes and obesity. The company also secured a USD 2.2 million cancer drug development project with collaborators like Merck, GSK, and McGill University in June 2019 to create 3D bioprinted tissues for assessing anti-cancer drug efficacy. Aspect collaborated with Maastricht University to develop viable 3D bioprinted kidney tissue for medical testing, utilizing its RX1 bioprinter.
In July 2024, Aspect announced a USD 200 million project backed by a USD 72.75 million investment from the Canadian and British Columbian governments. This multi-year initiative aims to establish a world-leading clinical biomanufacturing facility, advance Aspect's technology platform, and expand its therapeutic pipeline.

3D Bioprinting Solutions is a Russian biotechnology research laboratory focused on developing and commercializing bioprinting technologies. The company was founded by INVITRO, the largest private medical company in Russia, and officially opened its 3D Bioprinting Solutions laboratory in September 2013. Its core activities involve the development and production of bioprinters, bioinks, and biofabrication technologies for regenerative medicine and drug discovery applications.
One of the company's key products is the FABION bioprinter, capable of bioprinting without the need for organic or artificial scaffolds using a proprietary nanotechnology approach. In 2016, 3D Bioprinting Solutions launched the FABION 2, an advanced bioprinter that can print complex structures using tissue spheroids and a wide range of hydrogels with different polymerization mechanisms. The FABION two features a unique laser positioning system with an accuracy of five micrometers, enabling the printing of highly intricate structures.
In 2018, the company delivered its Organ.Aut magnetic 3D bioprinter to the International Space Station (ISS) for conducting experiments in microgravity conditions. The Organ.Aut successfully bioprinted a mouse's thyroid gland in space in December 2018, marking the first instance of living tissue being printed in outer space. In August 2019, the company bioprinted bone tissue aboard the ISS using the Organ.Aut.
3D Bioprinting Solutions has actively pursued collaborations with research institutions and commercial entities worldwide. In April 2019, the company announced plans to collaborate with laboratories from the US and Israel to deliver muscular tissue biomaterials to the ISS for bioprinting experiments using the Organ.Aut bioprinter.

3D Bioprinting Solutions

A.D.A.M. Bioprinting is a company developing an on-demand 3D bioprinting platform for manufacturing personalized implants. Their core technology, a Medical Device Production System, enables medical professionals to complete the entire process of 3D modeling, printing, and sterilization to create customized implants ready for implantation.
The company's initial focus is on producing orthopaedic bone implants for cranial, maxillofacial, general trauma, and orthopaedic oncology surgeries. However, A.D.A.M. Bioprinting plans to expand its offerings to include printed soft tissues in the future.
Founded in 2018, A.D.A.M. Bioprinting has its roots in Ukrainian aerospace and biotech engineering. The company operates with a research and development office in Ukraine, while its US-based entity holds intellectual property and handles business development and marketing functions.
In May 2022, A.D.A.M. Bioprinting was accepted into Elementa Labs, the virtual incubator program of the Mount Sinai Health System in New York. This program aims to optimize, expand, and advance the company's core technology platform, potentially leading to its commercialization in the US market.

A.D.A.M.

Advanced BioMatrix, a San Diego-based biotechnology company, develops advanced biomaterials and reagents for 3D cell culture applications, including cell cultivation, cell assays, bioprinting, and cell proliferation. The company's products have been utilized in groundbreaking research for drug development and 3D bioprinted tissue models, with over 5,000 citations in scientific publications as of September 2021. Advanced BioMatrix's offerings include hydrogels that mimic the extracellular matrix, facilitating cellular attachment, survival, and compatibility with various tissue types.
In September 2021, Advanced BioMatrix was acquired by BICO Group AB, a Swedish bioconvergence company focused on enhancing biology research, for approximately USD 15 million. Following the acquisition, Advanced BioMatrix became a subsidiary of CELLINK Bioprinting, operating under the BICO Group. The company generated approximately USD 3 million in revenue with an adjusted EBITDA margin of around 50% in its latest fiscal year prior to the acquisition.
Key customers and partnerships
Advanced BioMatrix has established collaborations with research institutes, pharmaceutical companies, and life science organizations worldwide. In June 2022, the company expanded its existing partnership with Lineage Cell Therapeutics for Lineage's HyStem cell/drug delivery technology, broadening its focus on manufacturing and supplying research-grade HyStem to the research community and developing clinical/commercial-grade material for Lineage's customers.
In August 2023, Advanced BioMatrix signed a distribution agreement with InSphero AG, a pioneer in 3D cell culture and organ-on-chip technology, to make InSphero's patented Akura Plate Technology available to researchers in the US market. This collaboration aims to expand the application range for scientists and drug developers by combining Advanced BioMatrix's biomaterials with InSphero's Akura Plates for scaffold-based organoid and spheroid cultures.

Advanced Biomatrix

Advanced Solutions Life Sciences, a wholly-owned subsidiary of Advanced Solutions, Inc., is a global leader in 3D biofabrication, headquartered in Louisville, Kentucky. The company pioneered the BioAssemblyBot, the world's first 6-axis robotic human tissue printer capable of systematically reproducing organoids. Their patented 3D printed blood vessel technology, derived from human fat tissue, empowers customers to advance the science of 3D organ printing. Advanced Solutions Life Sciences offers expertise in regenerative medicine, bioinks, 3D tissue assays for drug discovery and testing, 3D tissue modeling, and 3D printing services.
In May 2018, the company expanded its operations by opening a second biofabrication facility and laboratory in Manchester, New Hampshire. This strategic expansion aimed to contribute to curative organ printing solutions and establish the company as a prominent corporate citizen in Manchester.
In January 2023, Advanced Solutions Life Sciences partnered with Molecular Devices, a bioscience company, to develop 3D biology automation solutions. They jointly developed the BioAssemblyBot 400 (BAB 400) for Drug Discovery, integrating Advanced Solutions' bioprinting platform with Molecular Devices' ImageXpress Cellular Imaging System. This automated platform enables consistent, large-scale production of organoid models, enhancing drug discovery research.

Advanced Solutions Life Sciences

Allegro 3D is a bioprinting company specializing in high-throughput and high-precision 3D printing technology for fabricating tissue models at an industrial scale. The company was acquired by BICO, a Swedish bioconvergence company, in May 2022 for an upfront enterprise value of USD 6 million. Allegro 3D's patented light-based digital light processing (DLP) bioprinting technology enables direct printing into multi-well plates, allowing customers to significantly increase their output of biofabricated constructs for applications in regenerative medicine and drug discovery workflows. The company's flagship product, the STEMAKER Model D, utilizes extrusion-based bioprinting to produce bio/organic parts using liquid feedstock. As of 2022, Allegro 3D was expected to generate approximately USD 1 million in revenue with positive EBITDA margins. The acquisition complements BICO's existing portfolio of bioprinters and strengthens its position as a global leader in providing bioprinting solutions.

Allegro 3D

Developing and selling bioprinter devices that can be used by hospitals, research institutes, and other organizations seeking to print biological substitutes and materials.

Companies that use propietary or third-party printers to produce and sell bioprinted tissues, including impants, organ replacement, and other types of tissues.

Companies that are developing materials and bioinks, that can be used in bioprinting devices. This includes material technologies and nanofibers.

3D printing enables bioprinting devices, which rely on a similar design and operating model

Startups in this hub are able to customize the bioprinted models to suit each patient

AI/ML is used in the design and optimization of 3D models that can be bioprinted

Aspect Biosystems

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless